These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11909981)

  • 21. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress.
    Nataraj J; Manivasagam T; Thenmozhi AJ; Essa MM
    Nutr Neurosci; 2016 Jul; 19(6):237-46. PubMed ID: 25730317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U; Del Dotto P
    Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
    Guo CH; Cao T; Zheng LT; Waddington JL; Zhen XC
    Acta Pharmacol Sin; 2020 Apr; 41(4):499-507. PubMed ID: 32112040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs used to treat Parkinson's disease, present status and future directions.
    Abdel-Salam OM
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.
    Iida M; Miyazaki I; Tanaka K; Kabuto H; Iwata-Ichikawa E; Ogawa N
    Brain Res; 1999 Aug; 838(1-2):51-9. PubMed ID: 10446316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
    Spathis AD; Asvos X; Ziavra D; Karampelas T; Topouzis S; Cournia Z; Qing X; Alexakos P; Smits LM; Dalla C; Rideout HJ; Schwamborn JC; Tamvakopoulos C; Fokas D; Vassilatis DK
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3999-4004. PubMed ID: 28348207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine receptors, motor responses, and dopaminergic agonists.
    Luquin-Piudo MR; Sanz P
    Neurologist; 2011 Nov; 17(6 Suppl 1):S2-8. PubMed ID: 22045321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease.
    Chen LW; Wang YQ; Wei LC; Shi M; Chan YS
    CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):273-81. PubMed ID: 17691984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH
    Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
    Jeon MY; Lee WY; Kang HY; Chung EJ
    Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.